Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Astaxanthin Market Expected to Exceed $1.2 Billion By 2026 Leading the Nutraceutical Segment for Lucrative Growth


News provided by

Financialnewsmedia.com

01 Jul, 2021, 12:30 GMT

Share this article

Share toX

Share this article

Share toX

Financialnewsmedia.com News Commentary

PALM BEACH, Fla., July 1, 2021 /PRNewswire/ -- Astaxanthin may be the most important, potent supplements that most people don't even know exists. Astaxanthin is a powerful, naturally occurring carotenoid pigment that's found in certain marine plants and animals. It is this that causes the pink or red color in salmon, lobster, trout and seafood. Often called "the king of the carotenoids," Astaxanthin is recognized as being one of the most powerful antioxidants found in nature. Antioxidants are essential for helping combat free radical and oxidative damage to help support a healthy aging process and boost immunity. People take Astaxanthin because of its valuable antioxidant properties. Astaxanthin is 800x stronger than CoQ10, 6,000x stronger than Vitamin C, and 100x stronger than Vitamin E when it comes to antioxidant activity. Astaxanthin helps improve cellular function, and has been linked to improving healthy blood flow, hypertension, improved cardiovascular health, immune health, joint pain, eye health, cognitive alertness and muscle recovery from exercise. Moreover, it has been linked to helping smooth wrinkles, make age spots smaller, and maintain skin moisture. A report from Market Research Future said that because Astaxanthin is said to have many health values it is projected that the Astaxanthin Market is expected to register a CAGR of 7.7% to reach USD 1,206.52 Million by 2026. "It's been linked to heart health, endurance, healthier skin, joint pain and may even be applied in future cancer treatment. As a result of this, astaxanthin finds usages in more than a few industries, counting food and beverages, pharmaceuticals, animal feed, and nutraceuticals." Active companies in the markets this week include: Pressure BioSciences, Inc. (OTCQB: PBIO), Cyanotech Corporation (NASDAQ: CYAN), Perrigo Company plc (NYSE: PRGO), Medifast (NYSE: MED), Archer-Daniels-Midland Company (NYSE: ADM).

A report from Grand View added that: "The anti-inflammatory properties of astaxanthin help in reducing pain in the muscles, joints, and tendons of patients suffering from chronic arthritis. Furthermore, increasing prevalence of diseases such as diabetes, cardiovascular diseases, cancer, and cognitive health problems is expected to drive the market. For instance, astaxanthin helps to increase general blood flow and reduces blood sugar in patients with blood pressure and diabetes. Astaxanthin in the form of nutraceuticals is also being used to prevent the occurrence of chronic diseases, improve health, and delay the aging process. With the growing interests in the field of dermatology, skin homeostasis benefits of astaxanthin such as antioxidant, photoprotective, and anti-inflammatory effects have been proposed." The Market Research Report concluded: "Surging demand for natural astaxanthin is expected to create profitable growth opportunities for the vendors active in the global astaxanthin market."

Pressure BioSciences, Inc. (OTCQB: PBIO) BREAKING NEWS: Pressure BioSciences Novel UST™ Platform Delivers Breakthrough Nanoemulsion Processing for One of the World's Most Potent Antioxidants - Astaxanthin - Pressure BioSciences, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced the application of its Ultra Shear Technology™ ("UST™") platform for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, the Company reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin ("AsX"), in extremely fine and uniform, monodisperse nanoemulsions of oil in water – critically important for fast and efficient absorption by the water-based biochemistry of humans and animals.

Astaxanthin is a natural red pigment produced by the microalgae Haematococcus pluvialis. It is responsible for the red coloration of krill and other crustaceans, and in turn, the familiar coloration of salmon and flamingos which feed on them.

As an antioxidant, AsX is 6000 times more powerful than vitamin C, 800 times more powerful than CoQ10, and 100 times more powerful than vitamin E [1]. In clinical studies, AsX has been shown to neutralize free radicals, greatly reducing oxidative stress [2], enhance natural immune response [3], improve muscle endurance and exercise performance [4], support cardiovascular, neural/cognitive and ocular health [5, 6, 7], protect skin against UV damage and premature aging [8], favorably modulate specific cell signaling pathways involved in cancer cell death [9], and even improve sperm motility in male infertility. Recent studies have suggested that AsX may help alleviate progression of COVID-19 into severe cytokine storm condition [10,11]. Further, AsX can cross the blood–brain barrier and has been shown to increase gene expression of several proteins known to be involved in injured brain recovery [12]. 

It is particularly important for antioxidants be water-soluble, allowing them to circulate freely through the blood. However, because AsX is oil-based and intrinsically water-insoluble, oral/gastrointestinal and topical absorption of AsX is typically less than 10%, unless it is effectively solubilized in dietary fats or provided in a lipid-based formulation [13].  Even then, AsX in oil is typically delivered in large droplets that pass through the body with very low overall absorption efficiency. 

Gary B. Smejkal, Senior Research Scientist at PBI, explained the breakthrough achieved by the Company: "Nanoemulsions produced by PBI's UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter [14]. Because these particles are so small, they do not scatter light and thus appear as clear ruby red liquids that disperse freely in water or other clear beverages. The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published [15]."

Mr. Smejkal continued: "Our initial stability studies have already shown that UST-processed AsX nanoemulsions are stable for at least four months at room temperature without any measurable change in oil droplet size, coalescence, or phase separation. We used AsX as a model compound to demonstrate the power of our UST platform technology. Our approach will be readily suitable to prepare nanoemulsions of other carotenoids and a wide range of fat-soluble vitamins and dietary supplements. We believe that the implications of PBI's UST platform for AsX and for a multitude of other oil-soluble nutraceuticals will undoubtedly be dramatic in the marketplace."

Mr. Richard T. Schumacher, President & CEO of PBI, commented: "The global astaxanthin market size was estimated at USD 1.0 billion in 2019 [16]. PBI is laser-focused on exploring the opportunities for our UST platform to profoundly alter the effectiveness and competitiveness of a great number of lucrative nutraceutical products. We have already begun discussions with prospective partners worldwide who are interested in using UST for production and commercialization of astaxanthin and other nutraceutical nanoemulsions. We remain optimistic that we will meet our stated goal of releasing our initial UST-based instrument to the market before the end of 2021. As previously announced, we intend to make this system available through a lease/royalty business model."  CONTINUED…  Read this full release and more news for Pressure BioSciences at:  https://www.financialnewsmedia.com/news-pbio/ 

Other recent developments in the markets include:

Cyanotech Corporation (NASDAQ: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, recently announced financial results for the fourth quarter and fiscal year 2021, ended March 31, 2021.

Commenting on the fiscal year results (changes shown vs. fiscal 2020), Cyanotech's Chief Executive Officer, Gerald R. Cysewski, Ph.D., said:  "Net sales increased slightly over the prior year, however, gross profit was negatively impacted by higher spirulina costs per kilo driven by lower production volumes. We generated $2.4 million in cash from operations, deleveraged the balance sheet by $1.7 million, and increased our capital investments including the installation of a new tablet press. During the fourth quarter, we launched new labels for both our BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® products. The new labels were well received in the marketplace."

Perrigo Company plc (NYSE: PRGO) recently announced financial results from continuing operations for the first quarter of fiscal year 2021 ended April 3, 2021. The Consumer Self-Care Americas ("CSCA") segment, the Consumer Self-Care International ("CSCI") segment and Corporate are included in results from continuing operations. Financial results from the generic Rx pharmaceuticals business are reported as discontinued operations. All comparisons are against the prior-year fiscal first quarter, unless otherwise noted.

President and CEO, Murray S. Kessler commented, "Two years ago, we began our journey to transform Perrigo from a healthcare to a consumer self-care company and with the actions taken this quarter, that transformation is now nearly complete. On March 1, 2021, we announced the divestment of our generic Rx business, our tenth transaction over the last two years, essentially completing our portfolio reconfiguration. We have made the necessary investments in infrastructure, capabilities, talent and capacity, and as a result have restored Perrigo to growth…".

Medifast (NYSE: MED), the global company behind one the fastest-growing health and wellness communities, OPTIVA®, recently released findings from a nationally-representative study on consumer health priorities and motivators.

In an earlier survey from December 2020*, the company found 63% of Americans had adopted new, positive health routines amid the pandemic, 96% of whom planned to continue embracing healthy habits in the new year. Six months into 2021, this new study, which surveyed 1,230 U.S. adults, found that almost all U.S. adults (93%) have health and wellness goals and 84% are actively working toward achieving them.

ADM Ventures, the corporate venture capital arm of ADM (NYSE: ADM) recently announced its collaboration with the Genesis Consortium. Genesis, founded by Silicon Valley-based investors SOSV and Mayfield Fund, is a global alliance of venture capital firms and corporations dedicated to supporting startups that leverage biology to promote human and planetary health. SOSV is the parent company of IndieBio, a leading startup accelerator and early-stage investor for biology-centered startups worldwide.

A global leader in human and animal nutrition, ADM actively partners with innovators advancing sustainability across the company's diverse, global business. Recently announced engagements with startup companies such as Air Protein, Spiber, and NET Power underscore ADM's dedication to sustainable innovation. This new partnership will accelerate the commercial launch and scale-up of startups that leverage biology to promote human and planetary health.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Pressure BioSciences, Inc. by the Company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact
email: editor@financialnewsmedia.com
+1(561)325-8757

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.